Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

926
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
926

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preventing Acute T Cell-Mediated Rejection Using Combined Normothermic Machine Perfusion and RNA Interference Technologies.

Transplantation·2026
Same author

Biomarkers in Ex Vivo Kidney Perfusion: A Shift Toward Omics Diagnostics.

Transplantation·2025
Same author

Transcriptomic profiling during normothermic machine perfusion of human kidneys reveals a pro-inflammatory cellular landscape and gene expression signature associated with severe ischemia-reperfusion injury and delayed graft function.

Frontiers in immunology·2025
Same author

Utilization and Transplantation of Unused Kidneys After Assessment Using Normothermic Machine Perfusion Technology.

Transplantation·2025
Same author

Successful AAV8 gene therapy on hepatic ex situ machine perfusion for mitochondrial neurogastrointestinal encephalomyopathy.

Journal of hepatology·2025
Same author

Subnormothermic acellular machine perfusion for prolonged preservation of human kidneys.

The British journal of surgery·2025
Same journal

Near-Infrared Spectroscopy (NIRS) Could Predict Graft Quality in Adult Liver Donors.

Journal of transplantation·2026
Same journal

Structured Multidisciplinary Care for Clinically Complex Kidney Transplant Recipients: A 12-Month Single-Center Cohort on Multidimensional Outcomes.

Journal of transplantation·2026
Same journal

Evaluation of Liver Transplantation Outcomes Using Grafts From Brain-Dead Donors With Warfarin-Associated Coagulopathy.

Journal of transplantation·2026
Same journal

Safe and Early Primary Closure of Open Abdomen in Pediatric Liver Transplantation Using a Doppler-Guided Tension Relief Strategy and Enhanced Wound Environment.

Journal of transplantation·2026
Same journal

Living Donor Intestinal Transplant: Indication, Techniques, Surgical Complications, and Outcomes in Recipients and Donors: A Systematic Review.

Journal of transplantation·2026
Same journal

A Qualitative Study of Cytomegalovirus Awareness and Experience in Kidney Transplant Recipients.

Journal of transplantation·2026
See all related articles

Related Experiment Video

Updated: May 3, 2026

Application of Hemostatic Devices in Laparoscopic Hepatectomy
04:23

Application of Hemostatic Devices in Laparoscopic Hepatectomy

Published on: April 19, 2022

2.3K

Systemic heparinisation in laparoscopic live donor nephrectomy.

Charlotte Crotty1, Yasmin Tabbakh1, Sarah A Hosgood1

  • 1Transplant Group, Department of Infection, Immunity and Inflammation, Leicester General Hospital, University of Leicester, Leicester LE5 4PW, UK.

Journal of Transplantation
|January 24, 2014
PubMed
Summary
This summary is machine-generated.

Omitting systemic heparinisation during laparoscopic live donor nephrectomy (LDN) is safe and feasible. This approach does not negatively impact donor or recipient outcomes, including graft survival.

More Related Videos

Single Port Donor Nephrectomy
07:17

Single Port Donor Nephrectomy

Published on: March 12, 2011

56.4K
Robot-Assisted Kidney Transplantation
07:30

Robot-Assisted Kidney Transplantation

Published on: July 19, 2021

4.0K

Related Experiment Videos

Last Updated: May 3, 2026

Application of Hemostatic Devices in Laparoscopic Hepatectomy
04:23

Application of Hemostatic Devices in Laparoscopic Hepatectomy

Published on: April 19, 2022

2.3K
Single Port Donor Nephrectomy
07:17

Single Port Donor Nephrectomy

Published on: March 12, 2011

56.4K
Robot-Assisted Kidney Transplantation
07:30

Robot-Assisted Kidney Transplantation

Published on: July 19, 2021

4.0K

Area of Science:

  • Nephrology
  • Surgical Innovation
  • Transplantation Immunology

Background:

  • Systemic heparinization is standard practice during laparoscopic live donor nephrectomy (LDN) to prevent renal vascular thrombosis.
  • The necessity and impact of heparin on outcomes in LDN remain subjects of investigation.

Purpose of the Study:

  • To compare the outcomes of laparoscopic live donor nephrectomy with and without systemic heparin administration.
  • To evaluate the safety and efficacy of omitting heparin in LDN.

Main Methods:

  • A retrospective analysis of 186 consecutive LDN patients (April 2008–November 2012).
  • Patients were divided into two groups: those who received systemic heparin (n=109) and those who did not (n=77).
  • Outcome measures included donor/recipient complications, initial graft function, and 12-month graft survival.

Main Results:

  • Demographics and warm ischemic times (WIT) were similar between heparinized and non-heparinized groups (WIT: 5 ± 3 minutes).
  • No significant differences were observed in complication rates, graft thrombosis, primary non-function, or 12-month graft survival.
  • Delayed graft function rates were comparable (3.6% vs. 1.2%, P=0.405).

Conclusions:

  • Omitting systemic heparinization in laparoscopic live donor nephrectomy is a safe and feasible strategy.
  • The absence of heparin does not compromise donor safety, recipient outcomes, or graft survival.